|
Glioblastoma Multiforme
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our group previously demonstrated epithelial membrane protein-2 (EMP2) involvement in pathologic angiogenesis in multiple cancer models including breast cancer and glioblastoma.
|
30646013 |
2019 |
|
Glioblastoma Multiforme
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The percentage of samples with high EMP2 expression was greater in GBMs than lower grade gliomas (90.0 vs. 52.6%, P = 0.001).
|
28887715 |
2018 |
|
Glioblastoma Multiforme
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest the potential for anti-EMP2 IgG1 as a promising novel anti-angiogenic therapy for GBM.
|
28597184 |
2017 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
EMP2 is a risk factor for glioma, and miR-133b should prove a potential target for glioma clinical prevention and treatment.
|
29940748 |
2019 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A large tissue microarray of lower grade glioma (WHO grades II-III, n = 19 patients) and glioblastoma (GBM) (WHO grade IV, n = 50 patients) was stained for EMP2.
|
28887715 |
2018 |
|
Glomerulonephritis, Minimal Change
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Lymphedema
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our group previously demonstrated epithelial membrane protein-2 (EMP2) involvement in pathologic angiogenesis in multiple cancer models including breast cancer and glioblastoma.
|
30646013 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to assess the potential of epithelial membrane protein 2 (EMP2) as a novel biomarker for CTC retrieval in breast cancer.
|
30218306 |
2019 |
|
Malignant neoplasm of endometrium
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results collectively suggest that anti-EMP2 therapy may be a novel method of reducing endometrial cancer stem cells.
|
28604744 |
2017 |
|
Malignant neoplasm of endometrium
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The residualizing agent, (64)Cu-DOTA anti-EMP2 minibody, achieved high uptake in endometrial cancer xenografts overexpressing EMP2 (10.2 ± 2.6, percent injected dose per gram (%ID/g) ± SD) with moderate uptake in wild-type HEC1A tumors (6.0 ± 0.1).
|
22585360 |
2013 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
EMP2 gene silencing and stable lung cancer cell lines established using EMP2 lentiviral shRNA induced K8 phosphorylation and reorganization.
|
26876307 |
2016 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
EMP2 functions as an oncogene in human endometrial and ovarian cancers; however, characteristics of EMP2 in urothelial cancer fulfill the criteria of a suppressor gene.
|
28408326 |
2017 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
In particular, EMP2 expression correlates with and helps regulate the expression of several cancer stem cell associated markers including aldehyde dehydrogenase 1 (ALDH1).
|
28604744 |
2017 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Translational research suggests that EMP2 may be targeted with antibodies to improve tumor control and survival in a variety of murine models and cancer types.
|
28720310 |
2017 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
It may also have value for imaging of tumor localization and therapeutic response in patients with EMP2-positive malignancies.
|
22585360 |
2013 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although the further investigation is needed to deeply understand the regulatory mechanisms of EMP2 in melanoma progression and metastasis, our results clarify the functions and mechanisms of autophagy in melanoma, and shed new light on novel targeted therapeutics for melanoma.
|
31333775 |
2019 |
|
Nasopharyngeal carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results showed a novel connection of NEAT1, miR-101-3p and EMP2 in NPC migration and radiation resistance.
|
29050268 |
2017 |
|
Nasopharyngeal carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These results support that loss of EMP2 is common, and its re-expression may serve as an approach to enhance radiation sensitivity in nasopharyngeal carcinoma.
|
28347228 |
2017 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Although the further investigation is needed to deeply understand the regulatory mechanisms of EMP2 in melanoma progression and metastasis, our results clarify the functions and mechanisms of autophagy in melanoma, and shed new light on novel targeted therapeutics for melanoma.
|
31333775 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Anti-EMP2 IgG1 reduced the expression and activity of ALDH and correspondingly reduced both primary and secondary tumor load.
|
28604744 |
2017 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Significantly correlation between the EMP2 immunointensity and primary tumor, nodal status, histological grade, vascular invasion and mitotic activity was identified.
|
25940704 |
2015 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer.
|
30218306 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The residualizing agent, (64)Cu-DOTA anti-EMP2 minibody, achieved high uptake in endometrial cancer xenografts overexpressing EMP2 (10.2 ± 2.6, percent injected dose per gram (%ID/g) ± SD) with moderate uptake in wild-type HEC1A tumors (6.0 ± 0.1).
|
22585360 |
2013 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Further, miR-133b can be considered a tumor suppressor because of its low expression and effects on cell apoptosis via down-regulating EMP2 expression and activating the apoptotic cell pathway in glioma.
|
29940748 |
2019 |